摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-p-Tolyl-pyridinium | 42850-08-8

中文名称
——
中文别名
——
英文名称
N-p-Tolyl-pyridinium
英文别名
1-(4-Methylphenyl)pyridin-1-ium
N-p-Tolyl-pyridinium化学式
CAS
42850-08-8
化学式
C12H12N
mdl
——
分子量
170.234
InChiKey
UEOOUARIKDTDPV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    3.9
  • 氢给体数:
    0
  • 氢受体数:
    0

文献信息

  • HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS
    申请人:Yu Chongxi
    公开号:US20100040548A1
    公开(公告)日:2010-02-18
    The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
    该发明提供了一种新型高渗透性复合物(HPC)或高渗透性前药(HPP)的组合物,包括抗微生物和抗微生物相关化合物,这些化合物能够以高渗透效率穿越生物屏障。HPP能够在穿越生物屏障后转化为母药活性药物或药物代谢物,从而可以治疗母药或代谢物所能治疗的疾病。此外,HPP能够到达母药可能无法进入或在目标区域获得足够浓度的区域,从而提供新的治疗方法。HPP可以通过各种给药途径向受试者施用,例如,局部给药到病情作用部位以高浓度,或者系统给药到生物体内并以更快速度进入全身循环。
  • IMAGE FORMING METHOD
    申请人:TOJO Kaoru
    公开号:US20110043578A1
    公开(公告)日:2011-02-24
    An image forming method including: at least recording an image by ejecting, by an ink jet method, an ink composition containing, at least one pigment as a coloring material, particles of at least one resin, at least one water-soluble organic solvent, and water, the ink composition having a surface tension of from 30 mN/m to 40 mN/m, to a recording medium having a single-layered or multi-layered pigment layer on or above at least one side of a support containing cellulose pulp as a main ingredient and a transferring amount of pure water to the recording medium, when measured by a dynamic scanning liquid absorptometer, of from 1 ml/m 2 to 15 ml/m 2 at a period of contact time of 100 ms and from 2 ml/m 2 to 20 ml/m 2 at a period of contact time of 400 ms, and heating the recorded image, is provided.
    一种图像形成方法,包括:通过喷射含有至少一种颜料作为着色材料、至少一种树脂颗粒、至少一种溶性有机溶剂和的油墨组合物,以喷墨方法至少记录一幅图像,所述油墨组合物表面张力为30 mN/m至40 mN/m,记录于一种记录介质上,所述记录介质具有单层或多层颜料层,该颜料层位于或位于包含纤维素浆料作为主要成分的支撑体的至少一侧上方,并且在100毫秒接触时间的动态扫描吸液仪测量下,将纯传递到记录介质,传递量为1 ml/m2至15 ml/m2,在400毫秒接触时间下,传递量为2 ml/m2至20 ml/m2,并加热记录的图像。
  • Method of screening for a carnitine transporter agonist or antagonist and its uses
    申请人:Sanofi-Aventis Deutschland GmbH
    公开号:EP1627922A1
    公开(公告)日:2006-02-22
    The present invention is directed to a method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a kit for carrying out the method of screening for a carnitine transporter agonist or for a carnitine transporter antagonist, to a method for the manufacture of a medicament for the treatment of a carnitine transporter deficiency, to methods of diagnosis of a carnitine transporter deficiency, to the use of a protein for the manufacture of an antibody reacting with a carnitine transporter, to an oligonucleotide and to methods of treatment of a carnitine transporter deficiency.
    本发明涉及一种肉碱转运体激动剂或肉碱转运体拮抗剂的筛选方法,涉及一种用于实施肉碱转运体激动剂或肉碱转运体拮抗剂筛选方法的试剂盒、肉碱转运体缺乏症的诊断方法,利用蛋白质制造与肉碱转运体反应的抗体,寡核苷酸,以及肉碱转运体缺乏症的治疗方法。
  • Recording ink, as well as, ink media set, ink cartridge, ink recorded matter, inkjet recording apparatus and inkjet recording method
    申请人:Ricoh Company, Ltd.
    公开号:EP1811002A2
    公开(公告)日:2007-07-25
    A recording ink containing at least a solid component which contains a colorant and a resin and is a solid at 25°C, a liquid component which has a higher boiling point than that of water and is a liquid at 25°C and water, wherein the total content of the liquid component in the recording ink is 20% by mass or less, the total content of the solid component in the recording ink is 20% by mass or more, and the total content of a resin component in the solid component is 40% by mass to 95% by mass relative to a total amount of the solid component is provided.
    本发明提供了一种记录墨,其中至少包含一种含有着色剂树脂且在 25°C 时为固体的固体成分、一种沸点高于且在 25°C 时为液体的液体成分和,其中液体成分在记录墨中的总含量为 20% (以质量计)或更少,固体成分在记录墨中的总含量为 20% (以质量计)或更多,固体成分中树脂成分的总含量相对于固体成分的总量为 40% (以质量计)至 95% (以质量计)。
  • Ink set for ink jet recording and ink jet recording method
    申请人:Canon Kabushiki Kaisha
    公开号:EP1964897A1
    公开(公告)日:2008-09-03
    An ink set for ink jet recording includes a black ink (101) and a plurality of color inks of different colors. The black ink (101) contains a pigment (103) as a coloring material. The color ink (102) having the highest brightness among the plurality of color inks has the highest surface tension among the plurality of color inks. The difference in surface tension between the black ink (101) and the color ink (102) having the highest brightness is 2 dyn/cm (mN/m) or less.
    用于喷墨记录的墨套件包括黑色墨 (101) 和多种不同颜色的彩色墨。黑色墨 (101) 包含作为着色材料的颜料 (103)。在多种彩色油墨中,亮度最高的彩色油墨 (102) 的表面张力在多种彩色油墨中最高。黑色墨 (101) 和亮度最高的彩色墨 (102) 之间的表面张力差为 2 达因/厘米(mN/m)或更小。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫